PL1639013T3 - Przeciwciała pan-kir2dl receptorów NK i ich zastosowanie w diagnostyce i leczeniu - Google Patents

Przeciwciała pan-kir2dl receptorów NK i ich zastosowanie w diagnostyce i leczeniu

Info

Publication number: PL1639013T3
Authority: PL; Poland
Prior art keywords: therapy; kir2dl; pan; diagnostic; receptor antibodies
Prior art date: 2003-07-02

Application number

PL04744115T

Other languages

English (en)

Inventor

Allessandro Moretta

Chiesa Mariella Della

Original Assignee

Innate Pharma

Univ Di Genova

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-02

Filing date

2004-07-01

Publication date

2013-02-28

2004-07-01 Application filed by Innate Pharma, Univ Di Genova filed Critical Innate Pharma

2013-02-28 Publication of PL1639013T3 publication Critical patent/PL1639013T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Virology (AREA)
Biotechnology (AREA)
Hematology (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Microbiology (AREA)
Oncology (AREA)
Wood Science & Technology (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Tropical Medicine & Parasitology (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Mycology (AREA)
Epidemiology (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)

PL04744115T 2003-07-02 2004-07-01 Przeciwciała pan-kir2dl receptorów NK i ich zastosowanie w diagnostyce i leczeniu PL1639013T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US48389403P	2003-07-02	2003-07-02
US54547104P	2004-02-19	2004-02-19
EP04744115A EP1639013B1 (en)	2003-07-02	2004-07-01	Pan-kir2dl NK-receptor antibodies and their use in diagnostic and therapy
PCT/IB2004/002464 WO2005003172A2 (en)	2003-07-02	2004-07-01	Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy

Publications (1)

Publication Number	Publication Date
PL1639013T3 true PL1639013T3 (pl)	2013-02-28

Family

ID=33567703

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04744115T PL1639013T3 (pl)	2003-07-02	2004-07-01	Przeciwciała pan-kir2dl receptorów NK i ich zastosowanie w diagnostyce i leczeniu

Country Status (21)

Country	Link
US (2)	US9902936B2 (pl)
EP (3)	EP2289939B1 (pl)
JP (5)	JP5015592B2 (pl)
KR (5)	KR101375153B1 (pl)
CN (2)	CN103588880B (pl)
AT (1)	ATE490984T1 (pl)
AU (2)	AU2004253770C1 (pl)
BR (2)	BRPI0412153B8 (pl)
CA (2)	CA2530272C (pl)
CY (1)	CY1113394T1 (pl)
DE (1)	DE602004030464D1 (pl)
DK (2)	DK1639013T3 (pl)
ES (2)	ES2393485T3 (pl)
HR (1)	HRP20120845T1 (pl)
IL (3)	IL172613A (pl)
MX (1)	MXPA05013923A (pl)
NO (4)	NO338818B1 (pl)
PL (1)	PL1639013T3 (pl)
PT (1)	PT1639013E (pl)
RU (2)	RU2404993C2 (pl)
WO (2)	WO2005003168A2 (pl)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090191213A9 (en) *	2003-07-02	2009-07-30	Novo Nordisk A/S	Compositions and methods for regulating NK cell activity
US7803376B2 (en)	2003-07-24	2010-09-28	Innate Pharma S.A.	Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
WO2005105849A1 (en) *	2004-04-30	2005-11-10	Innate Pharma	Compositions and methods for treating proliferative disorders such as nk-type ldgl
EP2287195B1 (en) *	2004-07-01	2019-05-15	Novo Nordisk A/S	Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
ATE499386T1 (de) *	2004-07-01	2011-03-15	Novo Nordisk As	An die rezeptoren kir2dl1, -2, -3, jedoch nicht kir2ds4, bindende antikörper und deren therapeutische verwendung
DE602005016683D1 (de)	2004-07-10	2009-10-29	Fox Chase Cancer Ct	Genetisch modifizierte, menschliche, natürliche killerzellenlinien:
JP5525689B2 (ja) *	2004-11-02	2014-06-18	ザガバメントオブザユナイテッドステイツオブアメリカアズリプレゼンティッドバイザセクレタリーデパートメントオブヘルスアンドヒューマンサービシーズ	過剰増殖性障害を処置するための組成物および方法
US8551483B2 (en)	2005-01-06	2013-10-08	Innate Pharma S.A.S.	Methods of treating viral infections by administering KIR2DL-binding antibodies
CN101103043A (zh)	2005-01-06	2008-01-09	诺和诺德公司	Kir结合剂和使用其的方法
EP3072522B1 (en)	2005-01-06	2019-04-24	Novo Nordisk A/S	Anti-kir combination treatments and methods
GT200600148A (es) *	2005-04-14	2006-11-22		Metodos para el tratamiento y la prevencion de fibrosis
AU2006301163B2 (en) *	2005-10-14	2012-02-23	Innate Pharma	Compositions and methods for treating proliferative disorders
US20100189723A1 (en)	2007-01-11	2010-07-29	Peter Andreas Nicolai Reumert Wagtmann	Anti-kir antibodies, formulations, and uses thereof
US8709411B2 (en)	2008-12-05	2014-04-29	Novo Nordisk A/S	Combination therapy to enhance NK cell mediated cytotoxicity
WO2010076788A2 (en) *	2008-12-29	2010-07-08	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
EP2535052B1 (en) *	2010-02-08	2016-09-07	Biotherapy Institute Of Japan	Method for producing nk cell enhancement-type blood product
CN106963947A (zh)	2010-11-22	2017-07-21	伊纳特医药股份有限公司	Nk细胞调节治疗和用于治疗血液恶性疾病的方法
SG10201603962TA (en)	2011-05-25	2016-07-28	Innate Pharma Sa	Anti-kir antibodies for the treatment of inflammatory disorders
US20140234342A1 (en)	2011-06-21	2014-08-21	Innate Pharma	Nkp46-mediated nk cell tuning
JO3370B1 (ar) *	2011-11-10	2019-03-13	Regeneron Pharma	طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
CN103946236B (zh) *	2011-11-23	2018-02-16	弗·哈夫曼-拉罗切有限公司	表达cd40l的哺乳动物细胞及其用途
RU2682449C2 (ru) *	2012-09-19	2019-03-19	Иннейт Фарма	Связывающие kir3dl2 агенты
PL2904011T3 (pl)	2012-10-02	2018-01-31	Bristol Myers Squibb Co	Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
WO2015069785A1 (en)	2013-11-06	2015-05-14	Bristol-Myers Squibb Company	Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
EP3187583B1 (en) *	2014-08-29	2023-04-26	National University Corporation Hokkaido University	Monoclonal antibody against kir2ds1
EP3212227B1 (en)	2014-10-28	2020-01-15	Children's University Hospital Tübingen	Treatment of pediatric bcp-all patients with an anti-kir antibody
CN113713091A (zh)	2015-02-06	2021-11-30	新加坡国立大学	工程免疫细胞及其用途和生产方法
TN2017000440A1 (en)	2015-04-17	2019-04-12	Bristol Myers Squibb Co	Compositions comprising a combination of an anti-pd-1 antibody and another antibody
CN107667173A (zh)	2015-05-06	2018-02-06	斯尼普技术有限公司	改变微生物种群和改善微生物群
EA201792573A1 (ru)	2015-05-21	2018-04-30	Харпун Терапьютикс, Инк.	Триспецифические связанные белки и способы их применения
IL274572B2 (en)	2015-07-16	2024-01-01	Biolinerx Ltd	Compositions and methods for treating cancer
EP3370768B9 (en) *	2015-11-03	2022-03-16	Janssen Biotech, Inc.	Antibodies specifically binding pd-1 and their uses
US20190038713A1 (en)	2015-11-07	2019-02-07	Multivir Inc.	Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
WO2017201502A1 (en)	2016-05-20	2017-11-23	Biohaven Pharmaceutical Holding Company Ltd.	Use of glutamate modulating agents with immunotherapies to treat cancer
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
GB201609811D0 (en)	2016-06-05	2016-07-20	Snipr Technologies Ltd	Methods, cells, systems, arrays, RNA and kits
US20190233534A1 (en)	2016-07-14	2019-08-01	Fred Hutchinson Cancer Research Center	Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
GB201616365D0 (en) *	2016-09-27	2016-11-09	Helsingin Yliopisto	Non-genetic modification of enveloped viruses
JP7542946B2 (ja)	2016-09-27	2024-09-02	ボードオブリージェンツ，ザユニヴァーシティーオブテキサスシステム	マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法
CN110072540B (zh)	2016-10-12	2023-06-02	得克萨斯州大学系统董事会	用于tusc2免疫治疗的方法和组合物
US20190248895A1 (en)	2016-10-21	2019-08-15	Innate Pharma	Treatment with anti-kir3dl2 agents
WO2018111902A1 (en)	2016-12-12	2018-06-21	Multivir Inc.	Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
KR102775647B1 (ko)	2017-03-31	2025-03-06	브리스톨-마이어스 스큅 컴퍼니	종양을 치료하는 방법
BR112019020909A2 (pt)	2017-04-05	2020-05-12	Korea Research Institute Of Bioscience And Biotechnology	Proteína de fusão ativadora de célula nk, célula nk e composição farmacêutica incluindo a mesma
AU2018265856B2 (en)	2017-05-12	2023-04-27	Harpoon Therapeutics, Inc.	Mesothelin binding proteins
US12116406B2 (en)	2017-05-26	2024-10-15	Fred Hutchinson Cancer Center	Anti-CD33 antibodies and uses thereof
CN107261304A (zh) *	2017-06-05	2017-10-20	中国兽医药品监察所	一种奶牛的布鲁氏菌病免疫试剂盒及其应用
US20190038733A1 (en)	2017-08-10	2019-02-07	National University Of Singapore	T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
IL315737A (en)	2017-10-13	2024-11-01	Harpoon Therapeutics Inc	B-cell maturation antigen-binding proteins
HRP20241268T1 (hr)	2017-10-13	2024-12-06	Harpoon Therapeutics, Inc.	Trispecifični proteini i postupci primjene
US20200239577A1 (en)	2017-10-15	2020-07-30	Bristol-Myers Squibb Company	Methods of treating tumor
CN108060137B (zh) *	2017-12-26	2021-07-02	博生吉医药科技(苏州)有限公司	Il7和il21修饰的nk92细胞、制备方法及其应用
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
EA202091887A1 (ru)	2018-02-08	2020-10-23	Драгонфлай Терапьютикс, Инк.	Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
DK3749346T3 (da)	2018-02-08	2024-09-09	Dragonfly Therapeutics Inc	Antistof variable domænekombinationer rettet mod nkg2d-receptoren
WO2019164930A1 (en)	2018-02-20	2019-08-29	Dragonfly Therapeutics, Inc.	Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
EP3768698B1 (en)	2018-03-19	2025-02-12	MultiVir Inc.	Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
PE20210665A1 (es)	2018-03-23	2021-03-31	Bristol Myers Squibb Co	Anticuerpos contra mica y/o micb y sus usos
US10760075B2 (en)	2018-04-30	2020-09-01	Snipr Biome Aps	Treating and preventing microbial infections
AU2019246043B2 (en)	2018-03-25	2024-07-04	Snipr Biome Aps.	Treating and preventing microbial infections
EP3774911A1 (en)	2018-03-30	2021-02-17	Bristol-Myers Squibb Company	Methods of treating tumor
KR20210008408A (ko)	2018-05-23	2021-01-21	싱가포르국립대학교	T-세포 악성 종양의 면역요법을 위한 cd2 표면 발현 및 키메라 항원 수용체의 발현에 대한 차단
WO2020033630A1 (en)	2018-08-08	2020-02-13	Dragonfly Therapeutics, Inc.	Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
US12378318B2 (en)	2018-08-08	2025-08-05	Dragonfly Therapeutics, Inc.	Proteins binding NKG2D, CD16 and a tumor-associated antigen
EA202091888A1 (ru)	2018-08-08	2020-10-23	Драгонфлай Терапьютикс, Инк.	Вариабельные домены антител, нацеленные на рецептор nkg2d
EP3849565A4 (en)	2018-09-12	2022-12-28	Fred Hutchinson Cancer Research Center	REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
WO2020061482A1 (en)	2018-09-21	2020-03-26	Harpoon Therapeutics, Inc.	Egfr binding proteins and methods of use
SG11202103022WA (en)	2018-09-25	2021-04-29	Harpoon Therapeutics Inc	Dll3 binding proteins and methods of use
WO2020106983A1 (en)	2018-11-21	2020-05-28	Board Of Regents, The University Of Texas System	Methods and compositions for treating cancer
WO2020127965A1 (en)	2018-12-21	2020-06-25	Onxeo	New conjugated nucleic acid molecules and their uses
KR20220016155A (ko)	2019-05-30	2022-02-08	브리스톨-마이어스 스큅 컴퍼니	면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
EP3977132A1 (en)	2019-05-30	2022-04-06	Bristol-Myers Squibb Company	Cell localization signature and combination therapy
JP2022534967A (ja)	2019-05-30	2022-08-04	ブリストル－マイヤーズスクイブカンパニー	多腫瘍遺伝子シグネチャーおよびその使用
WO2021024020A1 (en)	2019-08-06	2021-02-11	Astellas Pharma Inc.	Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021113644A1 (en)	2019-12-05	2021-06-10	Multivir Inc.	Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
CN111424012A (zh) *	2020-03-30	2020-07-17	威海市中心医院	一种nk细胞培养用的饲养细胞去增殖能力的处理方法
MX2022013944A (es)	2020-05-06	2022-11-30	Dragonfly Therapeutics Inc	Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
AR122644A1 (es)	2020-06-19	2022-09-28	Onxeo	Nuevas moléculas de ácido nucleico conjugado y sus usos
MX2023000197A (es)	2020-07-07	2023-02-22	BioNTech SE	Arn terapeutico para el cancer positivo para vph.
AU2021334361A1 (en)	2020-08-31	2023-05-11	Bristol-Myers Squibb Company	Cell localization signature and immunotherapy
WO2022120179A1 (en)	2020-12-03	2022-06-09	Bristol-Myers Squibb Company	Multi-tumor gene signatures and uses thereof
WO2022135666A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Treatment schedule for cytokine proteins
WO2022135667A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Therapeutic rna for treating cancer
TW202245808A (zh)	2020-12-21	2022-12-01	德商拜恩迪克公司	用於治療癌症之治療性ｒｎａ
US20240000837A1 (en) *	2020-12-23	2024-01-04	H. Lee Moffitt Cancer Center And Research Institute Inc.	Inhibition of kir2dl2 for the enhancement of adoptive immunotherapies
SMT202500208T1 (it)	2020-12-28	2025-07-22	Bristol Myers Squibb Co	Composizioni anticorpali e metodi per il loro uso
JP2024501029A (ja)	2020-12-28	2024-01-10	ブリストル－マイヤーズスクイブカンパニー	Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
US20240101673A1 (en)	2021-02-03	2024-03-28	Mozart Therapeutics, Inc.	Binding agents and methods of using the same
JP2024508894A (ja)	2021-03-03	2024-02-28	ドラゴンフライセラピューティクス，インコーポレイテッド	Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
JP2024514530A (ja)	2021-04-02	2024-04-02	ザリージェンツオブザユニバーシティオブカリフォルニア	切断型ｃｄｃｐ１に対する抗体およびその使用
JP2024525758A (ja)	2021-07-13	2024-07-12	ビオンテック・ソシエタス・エウロパエア	がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
WO2023059333A1 (en)	2021-10-08	2023-04-13	3M Innovative Properties Company	Slot die assembly with tuned stiffness, reduced draw zone, and force budget
TW202333802A (zh)	2021-10-11	2023-09-01	德商拜恩迪克公司	用於肺癌之治療性rna(二)
EP4448095A1 (en)	2021-12-14	2024-10-23	Institut National de la Santé et de la Recherche Médicale (INSERM)	Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
JP2025500922A (ja)	2021-12-16	2025-01-15	ヴァレリオ・セラピューティクス	新規のコンジュゲートされた核酸分子及びその使用
EP4493575A1 (en)	2022-03-18	2025-01-22	Bristol-Myers Squibb Company	Methods of isolating polypeptides
EP4531916A1 (en)	2022-06-02	2025-04-09	Bristol-Myers Squibb Company	Antibody compositions and methods of use thereof
GB202209518D0 (en)	2022-06-29	2022-08-10	Snipr Biome Aps	Treating & preventing E coli infections
WO2024026385A1 (en) *	2022-07-28	2024-02-01	H. Lee Moffitt Cancer Center And Research Institute Inc.	Inhibition of kir2dl2 and/or kir2dl3 for the enhancement of adoptive immunotherapies
EP4610277A1 (en) *	2022-10-25	2025-09-03	Daiichi Sankyo Company, Limited	Method for avoiding immune rejection using agonist for inhibitory kir
KR20250120305A (ko)	2022-12-14	2025-08-08	아스텔라스 파마 유럽 비.브이.	Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
CN121712571A (zh)	2023-08-15	2026-03-20	百时美施贵宝公司	陶瓷羟基磷灰石色谱流通法
WO2025120867A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
AR134560A1 (es)	2023-12-08	2026-01-28	Astellas Pharma Inc	Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
WO2026033885A1 (en)	2024-08-08	2026-02-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025145207A1 (en)	2023-12-29	2025-07-03	Bristol-Myers Squibb Company	Combination therapy of kras inhibitor and treg-depleting agent
CN117883553B (zh) *	2024-01-12	2024-08-27	成都医学院	Pml-1蛋白在制备抑制细胞因子风暴的药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
US5776427A (en) *	1992-03-05	1998-07-07	Board Of Regents, The University Of Texas System	Methods for targeting the vasculature of solid tumors
US5539094A (en) *	1993-11-12	1996-07-23	La Jolla Cancer Research Foundation	DNA encoding Bcl-2-associated proteins
IL108501A (en) *	1994-01-31	1998-10-30	Mor Research Applic Ltd	Antibodies and pharmaceutical compositions containing them
US5583034A (en) *	1994-02-22	1996-12-10	La Jolla Institute For Allergy And Immunology	Enhancement of adoptosis using antisense oligonucleotides
US5808028A (en) *	1994-05-24	1998-09-15	The United States Of America As Represented By The Department Of Health And Human Services	Molecular clone of a P58 receptor protein and uses thereof
NZ298145A (en)	1994-12-29	1998-08-26	Yamanouchi Pharma Co Ltd	Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament
US6750044B1 (en)	1996-10-17	2004-06-15	Genentech, Inc.	Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
ES2270638T3 (es) *	1998-10-29	2007-04-01	Dakocytomation Denmark A/S	Deteccion de microorganismos acido-resistentes en las heces.
EP1179541B1 (en)	1999-04-28	2004-06-16	Board Of Regents, The University Of Texas System	Compositions and methods for cancer treatment by selectively inhibiting VEGF
KR100419555B1 (ko) *	2000-05-29	2004-02-19	주식회사유한양행	비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
US7803376B2 (en) *	2003-07-24	2010-09-28	Innate Pharma S.A.	Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
EP2287195B1 (en)	2004-07-01	2019-05-15	Novo Nordisk A/S	Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
AU2005321017B2 (en) *	2004-12-28	2011-02-24	Innate Pharma S.A.	Monoclonal antibodies against NKG2A
CN101103043A (zh) *	2005-01-06	2008-01-09	诺和诺德公司	Kir结合剂和使用其的方法
EP3072522B1 (en) *	2005-01-06	2019-04-24	Novo Nordisk A/S	Anti-kir combination treatments and methods
US8551483B2 (en) *	2005-01-06	2013-10-08	Innate Pharma S.A.S.	Methods of treating viral infections by administering KIR2DL-binding antibodies
AU2006301163B2 (en) *	2005-10-14	2012-02-23	Innate Pharma	Compositions and methods for treating proliferative disorders
US20100189723A1 (en)	2007-01-11	2010-07-29	Peter Andreas Nicolai Reumert Wagtmann	Anti-kir antibodies, formulations, and uses thereof
SG10201603962TA (en) *	2011-05-25	2016-07-28	Innate Pharma Sa	Anti-kir antibodies for the treatment of inflammatory disorders
US9789182B2 (en) *	2012-10-23	2017-10-17	Bristol-Myers Squibb Company	Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
WO2015069785A1 (en) *	2013-11-06	2015-05-14	Bristol-Myers Squibb Company	Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
US9884593B2 (en) *	2015-02-12	2018-02-06	Pro-Gard Products, Llc	Weapon mounting system

2004
- 2004-07-01 ES ES04744115T patent/ES2393485T3/es not_active Expired - Lifetime
- 2004-07-01 RU RU2006102960/10A patent/RU2404993C2/ru active
- 2004-07-01 PL PL04744115T patent/PL1639013T3/pl unknown
- 2004-07-01 ES ES10178580T patent/ES2725526T3/es not_active Expired - Lifetime
- 2004-07-01 AT AT04738967T patent/ATE490984T1/de not_active IP Right Cessation
- 2004-07-01 US US10/563,045 patent/US9902936B2/en not_active Expired - Fee Related
- 2004-07-01 KR KR1020067000109A patent/KR101375153B1/ko not_active Expired - Lifetime
- 2004-07-01 JP JP2006515738A patent/JP5015592B2/ja not_active Expired - Lifetime
- 2004-07-01 PT PT47441159T patent/PT1639013E/pt unknown
- 2004-07-01 EP EP10178580.6A patent/EP2289939B1/en not_active Expired - Lifetime
- 2004-07-01 CN CN201310057089.0A patent/CN103588880B/zh not_active Expired - Lifetime
- 2004-07-01 WO PCT/DK2004/000470 patent/WO2005003168A2/en not_active Ceased
- 2004-07-01 EP EP04744115A patent/EP1639013B1/en not_active Expired - Lifetime
- 2004-07-01 CN CN201310392765.XA patent/CN103467602B/zh not_active Expired - Lifetime
- 2004-07-01 EP EP04738967A patent/EP1673397B1/en not_active Expired - Lifetime
- 2004-07-01 WO PCT/IB2004/002464 patent/WO2005003172A2/en not_active Ceased
- 2004-07-01 KR KR1020127013323A patent/KR101420344B1/ko not_active Expired - Lifetime
- 2004-07-01 KR KR1020067000025A patent/KR20060079180A/ko not_active Ceased
- 2004-07-01 BR BRPI0412153A patent/BRPI0412153B8/pt not_active IP Right Cessation
- 2004-07-01 MX MXPA05013923A patent/MXPA05013923A/es active IP Right Grant
- 2004-07-01 RU RU2005140152/13A patent/RU2376315C2/ru active
- 2004-07-01 JP JP2006516606A patent/JP4871125B2/ja not_active Expired - Lifetime
- 2004-07-01 DK DK04744115.9T patent/DK1639013T3/da active
- 2004-07-01 CA CA2530272A patent/CA2530272C/en not_active Expired - Lifetime
- 2004-07-01 AU AU2004253770A patent/AU2004253770C1/en not_active Expired
- 2004-07-01 BR BRPI0412138A patent/BRPI0412138B8/pt not_active IP Right Cessation
- 2004-07-01 DE DE602004030464T patent/DE602004030464D1/de not_active Expired - Lifetime
- 2004-07-01 DK DK04738967.1T patent/DK1673397T3/da active
- 2004-07-01 KR KR1020137013482A patent/KR101444717B1/ko not_active Expired - Lifetime
- 2004-07-01 KR KR1020127002275A patent/KR101325023B1/ko not_active Expired - Lifetime
- 2004-07-01 AU AU2004253630A patent/AU2004253630B2/en not_active Expired
- 2004-07-01 HR HRP20120845TT patent/HRP20120845T1/hr unknown
- 2004-07-01 CA CA002530591A patent/CA2530591A1/en not_active Abandoned
2005
- 2005-12-15 IL IL172613A patent/IL172613A/en active IP Right Grant
- 2005-12-19 NO NO20056048A patent/NO338818B1/no unknown
- 2005-12-20 IL IL172700A patent/IL172700A/en active IP Right Grant
2006
- 2006-02-01 NO NO20060528A patent/NO338255B1/no unknown
2012
- 2012-04-06 JP JP2012087648A patent/JP5826697B2/ja not_active Expired - Lifetime
- 2012-11-28 CY CY20121101151T patent/CY1113394T1/el unknown
2015
- 2015-03-04 JP JP2015042824A patent/JP6556465B2/ja not_active Expired - Lifetime
- 2015-04-28 IL IL238490A patent/IL238490A0/en unknown
2016
- 2016-02-16 NO NO20160264A patent/NO342318B1/no unknown
- 2016-03-10 NO NO20160411A patent/NO343342B1/no unknown
2018
- 2018-01-22 US US15/876,839 patent/US11365393B2/en active Active
- 2018-04-16 JP JP2018078329A patent/JP2018153185A/ja active Pending

Also Published As

Publication number	Publication date
EP1639013A2 (en)	2006-03-29
EP2289939A3 (en)	2013-12-04
IL172613A (en)	2010-12-30
JP5826697B2 (ja)	2015-12-02
KR20060079180A (ko)	2006-07-05
ATE490984T1 (de)	2010-12-15
KR101420344B1 (ko)	2014-07-16
JP2007524612A (ja)	2007-08-30
KR101375153B1 (ko)	2014-03-18
RU2005140152A (ru)	2007-08-27
NO342318B1 (no)	2018-05-07
NO20056048L (no)	2006-04-03
BRPI0412153A (pt)	2006-08-22
WO2005003172A2 (en)	2005-01-13
EP1673397A2 (en)	2006-06-28
EP2289939A2 (en)	2011-03-02
US9902936B2 (en)	2018-02-27
ES2725526T3 (es)	2019-09-24
JP2015163068A (ja)	2015-09-10
IL172700A0 (en)	2006-04-10
BRPI0412153B1 (pt)	2019-07-30
NO20160411A1 (no)	2016-03-10
RU2376315C2 (ru)	2009-12-20
NO338818B1 (no)	2016-10-24
AU2004253630A1 (en)	2005-01-13
CN103588880A (zh)	2014-02-19
IL172613A0 (en)	2006-04-10
KR20120059659A (ko)	2012-06-08
AU2004253630B2 (en)	2010-11-25
CY1113394T1 (el)	2016-06-22
MXPA05013923A (es)	2006-08-11
WO2005003168A3 (en)	2005-05-06
NO338255B1 (no)	2016-08-08
IL238490A0 (en)	2015-06-30
US11365393B2 (en)	2022-06-21
RU2404993C2 (ru)	2010-11-27
NO20160264A1 (no)	2016-02-16
CA2530272A1 (en)	2005-01-13
DE602004030464D1 (de)	2011-01-20
AU2004253770B2 (en)	2009-10-29
JP5015592B2 (ja)	2012-08-29
HRP20120845T1 (hr)	2012-11-30
NO20060528L (no)	2006-02-01
NO343342B1 (no)	2019-02-04
AU2004253770C1 (en)	2010-04-15
BRPI0412138A (pt)	2006-08-15
KR101325023B1 (ko)	2013-11-04
CN103588880B (zh)	2019-09-17
EP1639013B1 (en)	2012-09-12
JP4871125B2 (ja)	2012-02-08
US20180216069A1 (en)	2018-08-02
CN103467602B (zh)	2018-04-10
DK1673397T3 (da)	2011-03-07
KR20060111440A (ko)	2006-10-27
ES2393485T3 (es)	2012-12-21
KR101444717B1 (ko)	2014-09-26
WO2005003172A3 (en)	2005-03-10
PT1639013E (pt)	2012-12-03
IL172700A (en)	2015-05-31
BRPI0412138B1 (pt)	2021-01-26
DK1639013T3 (da)	2013-01-07
RU2006102960A (ru)	2006-06-27
KR20120024998A (ko)	2012-03-14
CA2530272C (en)	2018-05-01
JP2008500947A (ja)	2008-01-17
JP6556465B2 (ja)	2019-08-07
BRPI0412153B8 (pt)	2021-05-25
EP2289939B1 (en)	2019-03-27
JP2018153185A (ja)	2018-10-04
HK1091662A1 (en)	2007-01-26
KR20130062379A (ko)	2013-06-12
AU2004253770A1 (en)	2005-01-13
CA2530591A1 (en)	2005-01-13
CN103467602A (zh)	2013-12-25
BRPI0412138B8 (pt)	2021-05-25
JP2012176953A (ja)	2012-09-13
EP1673397B1 (en)	2010-12-08
WO2005003168A2 (en)	2005-01-13
US20060263361A1 (en)	2006-11-23

Publication	Publication Date	Title
IL172613A0 (en)	2006-04-10	Pan-kir2dl nk-receptor antibodies and their use in diagnostic and therapy
EP2287195A3 (en)	2013-12-04	Pan-KIR2DL NK-receptor antibodies and their use in diagnostik and therapy
WO2004043361A3 (en)	2007-10-04	Compositions and methods for the treatment of natural killer cell related diseases
ATE295876T1 (de)	2005-06-15	Dedifferenzierte, programmierbare stammzellen monozytären ursprungs, sowie deren herstellung und verwendung
EP2322200A3 (en)	2011-07-27	Compositions and methods for the treatment of immune related diseases
WO2004047728A3 (en)	2006-11-30	Compositions and methods for the treatment of immune related diseases
NO20045521L (no)	2004-12-17	Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
EP2182006A3 (en)	2010-09-15	Compositions and methods for the treatment of immune related diseases
WO2008006895A3 (en)	2008-03-27	Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators
MXPA05013645A (es)	2006-02-24	Nuevos compuestos moduladores de los receptores de tipo ppar gama y su utilizacion en composiciones cosmeticas o farmaceuticas.
DE602005010876D1 (de)	2008-12-18	Neuartige biaromatische ppar-rezeptoren aktivierende zusammensetzungen und ihre verwendung in kosmetischen oder pharmazeutischen zusammensetzungen
WO2004024072A3 (en)	2006-03-16	Novel compositions and methods for the treatment of immune related diseases
WO2006107634A3 (en)	2007-04-19	Hair straightening compositions and methods
BR0314783A (pt)	2005-07-26	Pirróis 3,4-dissubstituìdos e seu uso no tratamento de doenças inflamatórias
MXPA05006081A (es)	2005-12-14	Nuevos compuestos moduladores de los receptores de tipo receptor activado proliferador de peroxisoma del subtipo (ppar gamma) y su uso en composiciones cosmeticas o farmaceuticas.
IL174594A (en)	2010-12-30	MANIPULATED NKT CELLS MODULATING THE Th1/Th2 BALANCE, USES AND THERAPEUTIC COMPOSITIONS THEREOF IN THE TREATMENT OF IMMUNE-RELATED DISORDERS
WO2005018540A3 (en)	2006-08-24	Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
WO2005094798A3 (en)	2006-04-13	Pharmaceutical compositions based on anticholinergics and ccr2 receptor antagonists
WO2006102643A3 (en)	2006-11-16	Stably transformed bone marrow-derived cells and uses thereof
MX2007000210A (es)	2007-08-02	Anticuerpos que se unen a los receptores kir2dl1,-2,3 pero no a kir2ds4 y su uso terapeutico.
WO2004004649A3 (en)	2007-09-20	Compositions and methods for the treatment of immune related diseases
ATE496047T1 (de)	2011-02-15	Phenylen-bis-oxazolidin-derivate und ihre verwendung als antikoagulantien
WO2004094598A3 (en)	2005-10-27	Methods of use for novel human polypeptides encoded by polynucleotides
WO2004083364A3 (de)	2004-12-02	Zellpräparat und verwendung des präparats zur behandlung von gelenken und knorpeldefekten, sowie verfahren zur herstellung
Donelson	2002	Re: Koes B, van Tulder M, Ostelo R, et al. Clinical guidelines for the management of low back pain in primary care: an international comparison.(Spine 2001; 26: 2504-14)